Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02106325 · ClinicalTrials.gov registry record · Phase 2
Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients
A Phase 2 study of Depression, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 2
- Study locations
NCT02106325 is a Phase 2 study of Depression that has completed, run by NYU Langone Health. The registered enrollment target is 21 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02106325, a Phase 2 study of Depression, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 2
- Study locations
Study Summary
Investigators will conduct a trial to evaluate the use of Ketamine as an alternate treatment for people with Major Depressive Disorder. This study plans to explore the potential that Ketamine's rapid antidepressant action holds for improving outcomes in patients presenting to the Emergency Department with severe depression. Since this is a controlled trial we will use an IV of Ketamine or and equivalent volume of Diphenhydramine. Subjects will be randomly assigned to receive Ketamine or Benadryl. Investigators will then compare measures of mood pre- and post-infusion in the Emergency Department. To supplement self-reported measures of depressive symptoms(e.g. mood), investigators will obtain objective measures of the biological aspects of Major Depressive Disorder.
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG Diphenhydramine
Study Locations (2)
New York
- Bellevue Hospital Center - New York
- NYU Langone Medical Center/Tisch Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-12 |
| Est. Completion | 2017-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02106325
The ClinicalTrials.gov registry entry for NCT02106325 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT02106325 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02106325 about?
NCT02106325 is a clinical study titled "Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients". Investigators will conduct a trial to evaluate the use of Ketamine as an alternate treatment for people with Major Depressive Disorder. This study plans to explore the potential that Ketamine's rapid antidepressant action holds for improving outcomes in patients presenting to the Emergency Departmen...
What is the current status of trial NCT02106325?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2013-12. Estimated completion is 2017-03.
What conditions does trial NCT02106325 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT02106325?
The interventions under investigation include: Ketamine (DRUG), Diphenhydramine (DRUG).
Who is sponsoring clinical trial NCT02106325?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02106325 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.